Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors

NCT05479812 is registered in ClinicalTrials.gov with Werewolf Therapeutics, Inc. as lead sponsor.

NCT NCT05479812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05479812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors
Lead sponsor
Werewolf Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 15, 2022
Completion date
April 22, 2026
Enrollment
156 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic solid tumor